Psilocybin-assisted Therapy for Alcohol Use Disorder
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Sydney
About this trial
To explore the effectiveness of psilocybin-assisted therapy on reducing alcohol consumption in a double-blind, randomised, phase II clinical trial.
Eligibility criteria
Qualifiers
Moderate to severe AUD according to the DSM-5 criteria
A desire to reduce or stop drinking
Consumed at least 21 standard drinks per week or ≥2 HDD (≥5 standard drinks/day for men; ≥4 for women) in the past week prior to screening
Aged ≥18 years old
Disqualifiers
Any psychotic disorder
Bipolar disorder type 1 or 2
Major depression with psychotic features
Any personality disorders
Trial design
Treatments tested in this trial
- Psilocybin
- Niacin
Treatment groups
90 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
University of Sydney
Lead sponsor
Woke Pharmaceuticals
Collaborator
Source ClinicalTrials.gov